Ajay Major, MD, MBA

Elated to share that our NCI K08 has been selected for funding! Deeply grateful to @hawkeyestudts and my colleagues @CUHematology @ACCORDSResearch for their persistence and coaching in bringing this lymphoma PRO-focused training award to fruition. #lymsm

2L CAR-T vs ASCT R/R PMBCL @BloodAdvances
- 252 pts; 26 CAR vs 157 salvage/ASCT
- 2L CAR: 77% axi, 23% liso
- ORR 91% vs 44%, CR 65% vs 15%
- mPFS NR vs 3.5 mos (HR 0.28!)
- 3-yr PFS 57% vs 21%, OS 78% vs 59%
- only 28% of salvage➡️ASCT; if got to ASCT, PFS/OS similar to CAR
Supports 2L CAR in PMBCL, altho chemosensitive dx still does well with ASCT. #lymsm #tcellrx
ashpublications.org/bloodadvances/…

Great analysis of PROs in BMT CTN trials @BloodAdvances
- 44 trials, 22 included PROs
- PRO inclusion increased from 38% to 85% since 2013
- only 11% specified PRO hypothesis
- 42% addressed missing data stats
- only 5/12 trials comparing arms showed significant PRO differences
- ISOQOL reporting quality: median 8/17 criteria met
PRO collection alone isn't enough. Hypothesis-driven approaches are needed + selection of appropriate (responsive!) PRO instruments. #bmtsm
doi.org/10.1182/blooda…

Love working with this diverse group of #lymsm clinician-scientists at @CUAnschutz @CUHematology!
We are looking forward to seeing you all at @ASH_hematology #ASH26.
cc @mana1981 @BradHaverkos @StevenBairMD @cduarte8490

Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadvances/…